These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 18770066)

  • 1. Exacerbation of diabetes related to exemestane treatment.
    Senkus-Konefka E; Orłowska-Kunikowska E; Dziadziuszko R; Jassem J
    Acta Oncol; 2008; 47(6):1167-9. PubMed ID: 18770066
    [No Abstract]   [Full Text] [Related]  

  • 2. Cancer: some reasons to be hopeful.
    Lancet; 2007 Feb; 369(9561):531. PubMed ID: 17307079
    [No Abstract]   [Full Text] [Related]  

  • 3. Exemestane following tamoxifen in postmenopausal women with primary breast cancer.
    Mouridsen HT
    J Clin Oncol; 2004 Sep; 22(18):3833-4. PubMed ID: 15365083
    [No Abstract]   [Full Text] [Related]  

  • 4. Exemestane or tamoxifen?
    Ueda M; Toji E; Noda S
    Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
    [No Abstract]   [Full Text] [Related]  

  • 5. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.
    Fallowfield LJ; Bliss JM; Porter LS; Price MH; Snowdon CF; Jones SE; Coombes RC; Hall E
    J Clin Oncol; 2006 Feb; 24(6):910-7. PubMed ID: 16484701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [ASCO 2006. Exemestane: a new drug for the adjuvant therapy of breast cancer].
    Perrone F
    Tumori; 2006; 92(4):suppl 1-9. PubMed ID: 17036536
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety of exemestane in the Intergroup Exemestane Study.
    Coombes RC; Bliss JM; Hall E
    J Clin Oncol; 2005 May; 23(13):3171-2. PubMed ID: 15860896
    [No Abstract]   [Full Text] [Related]  

  • 8. Metastatic breast cancer response after Exemestane withdrawal: a case report.
    Bhide SA; Rea DW
    Breast; 2004 Feb; 13(1):66-8. PubMed ID: 14759719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
    Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC
    Oncology; 2005; 69(6):471-7. PubMed ID: 16410685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.
    Winters L; Habin K; Gallagher J
    Clin J Oncol Nurs; 2007 Jun; 11(3):433-9. PubMed ID: 17623627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.
    Lønning PE; Geisler J; Krag LE; Erikstein B; Bremnes Y; Hagen AI; Schlichting E; Lien EA; Ofjord ES; Paolini J; Polli A; Massimini G
    J Clin Oncol; 2005 Aug; 23(22):5126-37. PubMed ID: 15983390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
    Johannessen DC; Engan T; Di Salle E; Zurlo MG; Paolini J; Ornati G; Piscitelli G; Kvinnsland S; Lonning PE
    Clin Cancer Res; 1997 Jul; 3(7):1101-8. PubMed ID: 9815789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exemestane-induced corneal epithelial changes.
    Papathanassiou M; Nikita E; Theodossiadis P; Theodossiadis GP; Vergados I
    Cutan Ocul Toxicol; 2010 Sep; 29(3):209-11. PubMed ID: 20470238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exemestane: new preparation. No tangible advance in metastatic breast cancer after tamoxifen failure.
    Prescrire Int; 2001 Aug; 10(54):108-9. PubMed ID: 11718178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exemestane: a novel aromatase inactivator for breast cancer.
    Jones SA; Jones SE
    Clin Breast Cancer; 2000 Oct; 1(3):211-6. PubMed ID: 11899645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
    Love RR; Hutson PR; Havighurst TC; Cleary JF
    Clin Cancer Res; 2005 Feb; 11(4):1500-3. PubMed ID: 15746052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
    Mamounas EP; Jeong JH; Wickerham DL; Smith RE; Ganz PA; Land SR; Eisen A; Fehrenbacher L; Farrar WB; Atkins JN; Pajon ER; Vogel VG; Kroener JF; Hutchins LF; Robidoux A; Hoehn JL; Ingle JN; Geyer CE; Costantino JP; Wolmark N
    J Clin Oncol; 2008 Apr; 26(12):1965-71. PubMed ID: 18332472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exemestane for advanced breast cancer.
    Med Lett Drugs Ther; 2000 Apr; 42(1076):35-6. PubMed ID: 10803175
    [No Abstract]   [Full Text] [Related]  

  • 19. Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment.
    Dixon JM
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):267-75. PubMed ID: 12113050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
    Jakesz R
    MMW Fortschr Med; 2005 Mar; 147(10):8. PubMed ID: 15803774
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.